论文部分内容阅读
目的对比置入药物洗脱支架(DES)后双联抗血小板治疗2年相比1年能否降低主要不良心血管事件。方法入选2006年1月至2007年12月行DES的患者221例,按照双联抗血小板治疗1年和2年分为2组,初级终点为主要不良心血管事件(心源性死亡、非致命性心肌梗死、靶血管再次血运重建的联合终点)。结果截止至2009年12月的随访结果显示服用氯吡格雷1年组和2年组的主要不良心血管事件发生率分别为4.3%和4.7%,P=0.80。结论置入DES术后延长双联抗血小板治疗时间至2年相比1年并未降低主要不良心血管事件。
Objectives To compare whether major adverse cardiovascular events can be reduced by 2-year antiplatelet therapy compared with 1 year after drug-eluting stent placement (DES). Methods Totally 221 patients undergoing DES from January 2006 to December 2007 were divided into 2 groups according to double antiplatelet therapy for 1 year and 2 years. The primary endpoint was major adverse cardiovascular event (cardiac death, non-fatal Myocardial infarction, target endovascular revascularization). Results The follow-up results as of December 2009 showed that the incidence of major adverse cardiovascular events in the 1-year and 2-year clopidogrel regimens was 4.3% and 4.7%, respectively, P 0.80. CONCLUSIONS: Prolonged double-antiplatelet therapy after 2-year DES treatment did not reduce major adverse cardiovascular events compared to 2 years.